10/566857

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV710216028US, on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 30, 2006

WW 91.B

IAP20 Rec'd FCTAPTO 3 0 JAN 2006

Docket No.: 17243/002001 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Melwyn Abreo et al.

22511

PATENT TRADEMARK OFFICE

Application No.: National Phase of

PCT/US2004/024542

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: PYRIDYL DERIVATIVES AND THEIR USE

AS THERAPEUTIC AGENTS

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and

10/566857

Application No.: National Phase of PCT/US2004/024542

Docket No.: 17243/002001

1AP20 Res'0 FGT/PTO 3 0 JAN 2006

Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0591, under Order No. 17243/002001.

Dated: January 30, 2006

Respectfully submitted,

T. Chyau Liang, Ph.D. Registration No.: 48,885

OSHA · LIANG LLP

1221 McKinney St., Suite 2800

Houston, Texas 77010

(713) 228-8600

(713) 228-8778 (Fax)



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paneauork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
"				Application Number	No Well Assigned 0 0 1	
11	NFORMATIC	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
l s	STATEMENT BY APPLICANT			First Named Inventor	Melwyn Abreo	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	17243/002001	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		1			

	•	FOREI	GN PATENT	DOCUMENTS	-	
Examiner	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
Initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	ВА	WO-03/045921	06-05-2003	FUJISAWA PHARMACEUTICAL CO., LTD., ET AL.		
	ВВ	EP-1 180 514	02-20-2002	MEIJI SEIKA KAISHA, LTD.		
_	ВС	WO-02/102778	12-27-2002	IWATA MASAHIRO		
	BD	EP-1 396 487	03-10-2004	YAMANOUCHI PHARMA CO. LTD.		
	BE	WO-00/44755	08-03-2000	ABBOTT LABORATORIES		
	BF	WO-01/62954	08-30-2001	NENON GENETICS, INC. ET AL.		
	BG	WO-03/075929	09-18-2003	JANSSEN PHARMACEUTICA N.V.		
	вн	WO-2004/065378	08-05-2004	WARNER-LAMBERT COMPANY LLC		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

İ	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	CA	International Search Report for PCT/US2004/024542, published on February 10, 2005 (4 pages)				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Application No. (if known): Not Yet Assigned

Attorney Docket No.: 17243/002001

## IAP20 Rec'd FCT/PTO 3 0 JAN 2006

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV710216028US in an envelope addressed to:

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	January 30, 2006
	Date

Qua R.	Beauce			
Signature				
Ava R. B	rown			
Typed or printed name of person signing Certificate				
(713) 228-8600				
Registration Number, if applicable	Telephone Number			

Note:

Each paper must have its own certificate of mailing, or this certificate must identify

each submitted paper.

IDS (Citation) by Applicant (9 References) (1 page)